Goldman Sachs raised its rating on Stryker Corporation SYK from Neutral to Buy and increased its price target from $55 to $68.
Goldman Sachs noted, "Our thesis calls for improvements in both operational and financial performance as follows: (1) new CEO and a reset of expectations for 2013; (2) strong product portfolio/pipeline and diversified revenue base offer multiple growth opportunities; (3) shareholder-friendly capital allocation with a greater orientation to cash returns; (4) cost and quality control initiatives remain a source of margin opportunity; and (5) attractive relative valuation compared to other large-cap MedTech firms in our coverage universe."
Stryker Corporation closed at $54.57 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in